

AMENDMENT TO THE CLAIMS

1. (Canceled).

2. (Currently amended) A crystalline biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino)-2(R)-hydroxyindan-1-yl)amide hemihydrate of ~~Claim 1 further~~ characterized by the X-ray powder diffraction pattern comprising a peak at 5.2, 6.2, 12.6, 14.0, 15.6, 17.0, 18.8, 19.6, 20.0, or 22.6 ($\pm 0.1^\circ 2\theta$).

3. (Currently amended) A crystalline biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino)-2(R)-hydroxyindan-1-yl)amide hemihydrate of ~~Claim 1 further~~ characterized by the X-ray powder diffraction pattern comprising peaks at 5.2 and 6.2 ($\pm 0.1^\circ 2\theta$).

4. (Currently amended) A crystalline biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino)-2(R)-hydroxyindan-1-yl)amide hemihydrate of ~~Claim 1 further~~ characterized by the X-ray powder diffraction pattern comprising peaks at 15.6 and 18.8 ($\pm 0.1^\circ 2\theta$).

5. (Currently amended) A crystalline biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino)-2(R)-hydroxyindan-1-yl)amide hemihydrate of ~~Claim 1 further~~ characterized by the X-ray powder diffraction pattern comprising peaks at 5.2, 6.2, 12.6, 15.6, 18.8, and 20.0 ($\pm 0.1^\circ 2\theta$).

6. (Currently amended) A crystalline biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino)-2(R)-hydroxyindan-1-yl)amide hemihydrate of ~~Claim 1 further~~ characterized by the X-ray powder diffraction pattern comprising peaks at 5.2, 6.2, 12.6, 14.0, 15.6, 17.0, 18.8, 19.6, 20.0, and 22.6 ($\pm 0.1^\circ 2\theta$).

7.-8. (Canceled)

9. Due to a numbering error, no Claim 9 was ever presented.

10. through 26. (Canceled).

27. (Currently amended) A method of treating ~~or prophylactically treating~~ Alzheimer's disease comprising administering to a patient in need thereof an effective amount of the biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)-ethylideneamino)-2(R)-hydroxyindan-1-yl)amide hemihydrate of any one of Claims 2-6.

28. (Canceled).

29. (Currently amended) A method of treating ~~or prophylactically treating~~ schizophrenia comprising administering to a patient in need thereof an effective amount of the biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylaminoethylideneamino)-2(R)-hydroxyindan-1-yl)amide hemihydrate of any one of Claims 2-6.

30. through 33. (Canceled).